Update on hirsutism

Acta Dermatovenerologica Alpina, Pannonica et Adriatica

Volumn 17, Issue 3, 2008, Pages 103-119

  Al Robaee, Ahmad ^a   Al Zolibani, A ^a   Al Shobaili, Hani A ^a   Aslam, Muhammad ^a  

^a QASSIM UNIVERSITY   (Saudi Arabia)

Author keywords

Evaluation; Females; Hirsutism; Pathogenesis; Prevalence; Treatment

Indexed keywords

ANDROGEN; ANTIANDROGEN; CYPROTERONE ACETATE; DESOGESTREL; DIANE; EFLORNITHINE; ESTROGEN; ETHINYLESTRADIOL; FINASTERIDE; FLUTAMIDE; GESTAGEN; GESTODENE; GLUCOCORTICOID; GONADORELIN AGONIST; INSULIN SENSITIZING AGENT; LIVER ENZYME; METFORMIN; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; ROSIGLITAZONE; SPIRONOLACTONE; TESTOSTERONE DERIVATIVE; TROGLITAZONE;

ACNE; ALOPECIA; AMENORRHEA; ANDROGEN BLOOD LEVEL; ANDROGEN SYNTHESIS; ANOVULATION; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGENITAL ADRENAL HYPERPLASIA; CONSERVATIVE TREATMENT; DISEASE COURSE; DISEASE SEVERITY; DNA MICROARRAY; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRY SKIN; ETHNIC DIFFERENCE; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; HAIR DISEASE; HAIR FOLLICLE; HAIR GROWTH; HIGH TEMPERATURE PROCEDURES; HIRSUTISM; HORMONE ACTION; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LABORATORY TEST; LIVER TOXICITY; LOW LEVEL LASER THERAPY; METABOLIC SYNDROME X; MONOTHERAPY; MUTATIONAL ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OLIGOMENORRHEA; OPTIMAL DRUG DOSE; OVARY POLYCYSTIC DISEASE; OVULATION; PATHOGENESIS; PHOTOTHERAPY; PHYSICAL EXAMINATION; POPULATION RESEARCH; PRACTICE GUIDELINE; PRENATAL DIAGNOSIS; PREVALENCE; RACE DIFFERENCE; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SIDE EFFECT; SKIN EXAMINATION; TERATOGENICITY; TESTOSTERONE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; URINE COLOR; UTERUS BLEEDING; VIRILIZATION;

FEMALE; GONADAL STEROID HORMONES; HAIR REMOVAL; HIRSUTISM; HORMONE ANTAGONISTS; HUMANS;

EID: 55049110771     PISSN: 13184458     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (147)

1. Keegan A, Liao LM, Boyle M. "Hirsutism": a psychological analysis. J Health Psychol. 2003;8(3):327-45.
2. Lipton MG, Sherr L, Elford J, Rustin MH, Clayton WJ. Women living with facial hair: the psychological and behavioral burden. J Psychosom Res. 2006;61(2):161-8.
3. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078-82.
4. Sperling LC. Hair density in African Americans. Arch Dermatol. 1999;135:656-8.
5. Lee HJ, Ha SJ, Lee JH, Kim JW, Kim HO, Whiting DA. Hair counts from scalp biopsy specimens in Asians. J Am Acad Dermatol. 2002;46:218-21.
6. DeUgarte CM, Woods KS, Bartolucci AA, Azziz A. Degree of facial and body terminal hair growth in unselected black and white women: towards a populational definition of hirsutism. J Clin Endocrinol Metab. 2006;91:1345-50.
7. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981;140:815-30.
8. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440-7.
9. Hassa H, Tanir HM, Yýldýrým A, Penses T, Eskalen M, Mutlu FP. The hirsutism scoring system should be population specific. Fertil Steril. 2005;84(3):778-80.
10. Gruber DM, Berger UE, Sator MO, Horak F, Huber JC. Computerized assessment of facial hair growth. Fertil Steril. 1999;72:737-9.
11. Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev. 2000;21:363-92.
12. Rosenfield RL. Hirsutism and the variable response of the pilosebaceous unit to androgen. J Invest Dermatol Symp Proc. 2005;10(3):205-8.
13. Quinkler M, Sinha B, Tomlinson JW, Bujalska IJ, Stewart PM, Arlt W. Androgen generation in adipose tissue in women with simple obesity - a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5. J Endocrinol. 2004;183:331-42.
14. Rosner W. The functions of corticosteroid-binding globulin and sex hormone binding-globulin: recent advances. Endocr Rev. 1990;11:80-91.
15. Rosenfield RL. Hirsutism. N Engl J Med. 2005;353(24):2578-88.
16. Breckwoldt M, Zahradnik HP, Wieacker P. Hirsutism, its pathogenesis. Hum Reprod. 1989;4:601-4.
17. Falsetti L, Rosina B, De Fusco D. Serum levels of 3alpha-androstanediol glucuronide in hirsute and non hirsute women. Eur J Endocrinol. 1998;138:421-4.
18. Benitez R, Sir-Petermann T, Palomino A, Angel B, Maliqueo M, Perez F, Calvillan M. Prevalence of metabolic disorders among family members of patients with polycystic ovary syndrome. Rev Med Chil. 2001;129:707-12.
19. Legro RS, Bentley-Lewis R, Driscoll D, Wang SC, Dunaif A. Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab. 2002;87:2128-33.
20. Yýldýz BO, Yaralý H, Oduz H, Bayraktar M. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:2031-6.
21. Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril. 2005;83:1717-23.
22. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2002;26:883-96.
23. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome: a hypothesis. J Endocrinol. 2002;174:1-5.
24. Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum Reprod Update. 2005;11:357-74.
25. Xita N, Tsatsoulis A. Fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical and genetic association studies. J Clin Endocrinol Metab. 2006;91(5):1660-6.
26. Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev. 2005;26:251-82.
27. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003;24:278-301.
28. Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med. 2003;349:776-88.
29. Witchel SF, Smith R, Tomboc M, Aston CE. Candidate gene analysis in premature pubarche and adolescent hyperandrogenism. Fertil Steril. 2001;75:724-30.
30. Lajic S, Clauin S, Robins T, Vexiau P, Blanche H, Bellanne-Chantelot C, Wedell A. Novel mutations in CYP21 detected in individuals with hyperandrogenism. J Clin Endocrinol Metab. 2002;87:2824-9.
31. Bojunga J, Welsch C, Antes I, Albrecht M, Lengauer T, Zeuzem S. Structural and functional analysis of a novel mutation of CYP21B in a heterozygote carrier of 21-hydroxylase deficiency. Human Genetics. 2005;117:558-64.
32. Admoni O, Israel S, Lavi I, Gur M, Tenenbaum-Rakover Y. Hyperandrogenism in carriers of CYP21 mutations: the role of genotype. Clin Endocrinol. 2006;64,645-51.
33. Gaasenbeek M, Powell BL, Sovio U, Haddad L, Gharani N, Bennett A, Groves CJ, et al. Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. J Clin Endocrinol Metab. 2004;89:2408-13.
34. Cousin P, Calemard-Michel L, Lejeune H, Raverot G, Yessaad N, Emptoz-Bonneton A, Morel Y, et al. Influence of SHBG gene pentanucleotide TAAAA repeat and D327N polymorphism on serum sex hormone-binding globulin concentration in hirsute women. J Clin Endocrinol Metab. 2004;89:917-24.
35. Peters CJ, Nugent T, Perry LA, Davies K, Morel Y, Drake WM, Savage MO, et al. Cosegregation of a novel homozygous CYP11B1 mutation with the phenotype of non-classical congenital adrenal hyperplasia in a consanguineous family. Horm Res. 2007;67(4):189-93.
36. Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B, Arlt W. Beyond adrenal and ovarian androgen generation: increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:2760-66.
37. Eminović I, Komel R, Preželj J, Karamehić J, Gavrankapetanović F, Heljić B. Gene analysis of steroid 5 alpha-reductase 1 in hyperandrogenic women. Croat Med J. 2005;46:664-9.
38. Stanczyk FZ. Diagnosis of hyperandrogenism: biochemical criteria. Best Prac Res Clin Endocrinol Metab. 2006;20(2):177-91.
39. Goodarzi MO, Shah NA, Antoine HJ, Pall M, Guo X, Azziz R. Variants in the 5 alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. J Clin Endocrinol Metab. 2006;91(10):4085-91.
40. Ibrahim S, Aydin A. Hyperinsulinism and its interaction with hyperandrogenism in polycystic ovary syndrome. Obstet Gynecol Surv. 2000;55(5):321-8.
41. San Millan JL, Corton M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab. 2004;89:2640-46.
42. Ibáñez L, Ong K, Potau N, Marcos MV, de Zegher F, Dunger D. Insulin gene variable number of tandem repeat genotype and the low birth weight, precocious pubarche, and hyperinsulinism sequence. J Clin Endocrinol Metab. 2001;86:5788-93.
43. Ehrmann DA, Tang X, Yoshiuchi I, Cox NJ, Bell GI. Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:4297-300.
44. Ibáñez L, Marcos MV, Potau N, White C, Aston CE, Witchel SF. Increased frequency of the G972R variant of the insulin receptor substrate-1 (IRS-1) gene among girls with a history of precocious pubarche. Fertil Steril. 2002;78:1288-93.
45. Witchel SF, Trivedi RN, Kammerer C. Frequency of the T228A polymorphism in the SORBS1 gene in children with premature pubarche and in adolescent girls with hyperandrogenism. Fertil Steril. 2003;80:128-32.
46. Ehrmann DA, Schwarz PE, Hara M, Tang X, Horikawa Y, Imperial J, Bell GI et al. Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:1669-73.
47. Haddad L, Evans JC, Gharani N, Robertson C, Rush K, Wiltshire S, Frayling TM, et al. Variation within the type 2 diabetes susceptibility gene calpain-10 and polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:2606-10.
48. Escobar-Morreale HF, Peral B, Villuendas G, Calvo RM, Sancho J, San Millan JL. Common single nucleotide polymorphisms in intron 3 of the calpain-10 gene influence hirsutism. Fertil Steril. 2002;77:581-7.
49. Gonzalez A, Abril E, Roca A, Aragon MJ, Figueroa MJ, Velarde P, Royo JL, et al. CAPN10 alleles are associated with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:3971-76.
50. Gonzalez A, Abril E, Roca A, Aragon MJ, Figueroa MJ, Velarde P, Ruiz R, et al. Specitic CAPN10 gene haplotypes influence the clinical profile of polycystic ovary patients. J Clin Endocrinol Metab. 2003;88:5529-36.
51. Vollmert C, Hahn S, Lamina C, Huth C, Kolz M, Schöpfer-Wendels A, Mann K, et al. Calpain-10 variants and haplotypes are associated with polycystic ovary syndrome in Caucasians. Am J Physiol Endocrinol Metab. 2007;292(3):E836-44.
52. Guttmacher AE, Collins FS. Genomic medicine: a primer. N Engl J Med. 2002;347:1512-20.
53. Mooser V, Ordovas JM. 'Omic' approaches and lipid metabolism: are these new technologies holding their promises? Curr Opin Lipidol. 2003;14:115-9.
54. Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev 2000;21:347-62.
55. Carbunaru G, Prasad P, Scoccia B, Shea P, Hopwood N, Ziai F, Chang YT et al. The hormonal phenotype of non-classic 3β-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency. J Clin Endocrinol Metab. 2004;89:783-94.
56. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taytor K et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89:453-62.
57. Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod. 2004;19:41-7
58. Carmina E, Rosato F, Jannì A, Rizzo M, Longo RA, Relalive prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab. 2006; 91:2-6.
59. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223-36.
60. Yýldýz BO. Diagnosis of hyperandrogenism: clinical criteria. Best Pract Res Clin Endocrinolo Metab. 2006;20:167-76.
61. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet. 2005;365:2125-36.
62. Witchel SF. Hyperandrogenism in adolescents. Adolescent Medicine. 2002;13(1):89-99.
63. Therrell BL. Newborn screening for congenital adrenal hyperplasia. Endocrinol Metab Clin North Am. 2001;30:15-30.
64. Trakakis E, Laggas D, Salamalekis E, Creatsas G. 21-Hydroxylase deficiency: from molecular genetics to clinical presentation. J Endocrinol Invest. 2005;28(2):187-92.
65. Kamel N, Tonyukuk V, Emral R, Čorapcýodlu D, Baptemir M, Güllü S. The prevalence of late onset congenital adrenal hyperplasia in hirsute women from Central Anatolia. J Ankara Med School. 2003;25(2):65-76.
66. Gatee OB, Al Attia HM, Salama IA. Hirsutism in the United Arab Emirates: a hospital study. Postgrad Med J. 1996;72:168-71.
67. New MI. Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2006;91(11):4205-14.
68. Moran C, Azziz R, Carmina E, Dewailly D, Fruzzetti F, Ibanez L, Knochenhauer ES, et al. 21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study. Am J Obstet Gynecol. 2000;183:1468-74.
69. Huppert J, Chiodi M, Hillard PJ. Clinical and metabolic findings in adolescent females with hyperandrogenism. J Pediatr Adolesc Gynecol. 2004;17:103-8.
70. Golden SH, Ding J, Szklo M, Schmidt MI, Duncan BB, Dobs A. Glucose and insulin components of the metabolic syndrome are associated with hyperandrogenism in postmenopausal women: the atherosclerosis risk in communities study. Am J Epidemiol. 2004;160:540-8.
71. Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol. 2003;46:325-40.
72. Walch K, Grimm C, Nagele F, Huber J, Wölfler M, Vytiska-Binstorfer E, Unfried G, et al. Impaired glucose tolerance is associated with changes in clinical and biochemical parameters in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2006;85(7):869-73.
73. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK., Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141-6.
74. Ünlühýzarcý K, Karababa Y, Bayram F, Kelelptimur F. The investigation of insulin resistance in patients with idiopathic hirsutism. J Clin Endocrinol Metab. 2004;89:2741-4.
75. Azziz R. The hyperandrogenic-insulin resistant-acanthosis nigricans (HAIRAN) syndrome: therapeutic response. Fertil Steril. 1994;61:570-2.
76. Omar HA, Logsdon S, Richards J. Clinical profiles, occurrence, and management of adolescent patients with HAIR-AN syndrome. Sci World J. 2004;4:507-11.
77. Tekin Ö, Ipýk B, Avcý Z, Čatal F, Erarslan E, Delibapý T. Hirsutism: common clinical problem or index of serious disease? MedGenMed. 2004;6(4):56.
78. Hrnciar J. Clinical manifestations of the insulin resistance syndrome. The hormonal-metabolic syndrome X, the 5H syndrome and their etiopathogenesis. Vnitr Lek 1995;41:92-8.
79. Ünlühýzarci K, Gökçe C, Atmaca H, Bayram F, Keleptimur F. A detailed investigation of hirsutism in a Turkish population: idiopathic hyperandrogenemia as a perplexing issue. Exp Clin Endocrinol Diabetes. 2004;112(9):504-9.
80. Charmandari E, Kino T, Chrousos GP. Familial/sporadic glucocorticoid resistance: clinical phenotype and molecular mechanisms. Ann NY Acad Sci. 2004;1024:168-81.
81. van Rossum EFC, Lamberts SWJ. Glucocorticoid resistance syndrome: a diagnostic and therapeutic approach. Best Pract Res Clin Endocrinol Metab. 2006;20(4):611-26.
82. Jones ME, Boon WC, McInnes K, Maffei L, Carani C, Simpson ER. Recognizing rare disorders: aromatase deficiency. Nat Clin Pract Endocrinol Metab. 2007;3(5):414-21.
83. Mercurio MG, Gogstetter DS. Androgen physiology and the cutaneous pilosebaceous unit. J Gend Specif Med. 2000;3(4):59-64.
84. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinuclotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994;22:3181-6.
85. Sawaya ME, Shalita AR. Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopesia, hirsutism and acne. J Cutan Med Surg. 1998;3:9-15.
86. Rossi R, Tauchmanova L, Luciano A, Valentino R, Savastano S, Battista C, Di Martino M, Lombardi G. Functional hyperandrogenism detected by corticotropin and GnRH-analogue stimulation tests in women affected by apparently idiopathic hirsutism. J Endocrinol Invest. 2001;24:491-8.
87. Carmina E, Lobo RA. Hirsutism, alopecia and acne. In: Becker KL, editor. Principles and practice of endocrinology and metabolism. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 991-5.
88. Stanczyk FZ, Davis SR. Current perspectives on the use of androgens in women. Semin Reprod Med. 2006;24(2):78-85.
89. Ruutiainen K, Sannikka E, Santti R, Erkkola R, Adlercreutz H. Salivary testosterone in hirsutism: correlations with serum testosterone and the degree of hair growth. J Clin Endocrinol Metabol. 1987;64:1015-20.
90. Claman P, Graves GR, Kredentser JV, Sagle MA, Tummon TS, Fluker M. SOGC clinical practice guidelines. Hirsutism: evaluation and treatment. J Obstet Gynaecol Can. 2002;24:62-73.
91. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol. 2003;101:995-1006.
92. Curran DR, Moore C. What is the best approach to the evalution of hirsutism? J Fam Pract. 2005;54(5):465-7.
93. Dawber RPR. Guidance for the management of hirsutism. Cur Med Res Opinion. 2005;21(8):1227-34.
94. Gilchrist VJ, Hecht BR. A practical approach to hirsutism. Am Fam Physician. 1995;52(6):1837-46.
95. Goodman NF. AACE Hyperandrogenic guidelines: American Association of Clinical Endocrinologists medical guidelines for the diagnosis and treatment of hyperandrogenic disorders. Endocr Pract. 2001;7(2):120-34.
96. Hunter MH, Carek PJ. Evaluation and treatment of women with hirsutism. Am Fam Physician. 2003;67:2565-72.
97. Fraser IS & Kovacs G. Current recommendations for the diagnostic evaluation and follow-up of patients presenting with symptomatic polycystic ovary syndrome. Best Prac Res Clin Obstet Gynaecol. 2004;18(5):813-23.
98. Souter I, Sanchez LA, Perez M, Bartolucci AA, Azziz R. The prevalence of androgen excess among patients with minimal unwanted hair growth. Am J Obstet Gynecol. 2004;191(6):1914-20.
99. Azziz R, Hincapie L, Knochenhauer ES, Dewailly D, Fox L, Boots LR. Screening for 21-hydroxylase deficient non-classic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril. 1999;72:915-25.
100. Azziz R, Waggoner WT, Ochoa T, Knochenhauer ES, Boots LR. Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama. Fertil Steril. 1998;70:274-8.
101. Elter K, Ýmir G, Durmupod lu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod. 2002;17:1729-37.
102. Ibáñez L, de Zegher F. Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. Hum Reprod. 2003;18:57-60.
103. Inal MM, Yýldýrým Y, Taner CE. Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. Fertil Steril. 2005;84(6):1693-7.
104. Batukan C, Müderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril. 2006;85(2):436-40.
105. Batukan C, Müderris II, Özçelik B, Öztürk A. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecol Endocrinol. 2007;23(1):38-44.
106. Pehlivanov B, Mitkov M. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care. 2007;12(1):30-5.
107. Breitkopf DM, Rosen MP, Young SL, Nagamani M. Efficacy of second versus third generation oral contraceptives in the treatment of hirsutism. Contraception. 2003;67(5):349-53.
108. Rittmaster RS. Medical Treatment of Androgen-Dependent Hirsutism. J Clin Endocrinol Metab. 1995;80:2559-63.
109. Çiçek MN, Bala A, Çelik Ç, Akyürek C. The comparison of clinical and hormonal parameters in PCOS patients treated with metformin and GnRH analogue. Arch Gynecol Obstet. 2003; 268(2):107-12.
110. Carmina E, Lobo RA. Gonadotrophin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission. Hum Reprod. 1997;12(4):663-6.
111. New MI. An update of congenital adrenal hyperplasia. Ann N Y Acad Sci. 2004;1038:14-43.
112. Spritzer P, Billaud L, Thalabard JC, Birman P, Mowszowicz I, Raux-Demay MC, et al. Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. J Clin Endocrinol Metab. 1990;70:642-6.
113. Falsetti L, Gambera A, Platto C, Legrenzi L. Management of hirsutism. Am J Clin Dermatol. 2000;1(2):89-99.
114. Keleptimur F, Everest H, Ünlühýzarcý K, Bayram F, Pahin Y. A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. Eur J Endocrinol. 2004; 150:351-4.
115. Christy NA, Franks AS, Cross LB. Spironolactone for hirsutism in polycystic ovary syndrome. Ann Pharmacother. 2005;39(10):1517-21.
116. Barth J, Cherry C, Wojnarowska F, Dawber RPR. Cyproterone acetate for severe hirsutism: results of a double-blind dose-ranging study. Clin Endocrinol (Oxf). 1991;35:5-10.
117. Lumachi F, Rondinone R. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. Fertil Steril. 2003;79(4):942-6.
118. Sert M, Tetiker T, Kýrým S. Comparison of the efficiency of anti-androgenic regimens consisting of spironolactone, Diane 35, and cyproterone acetate in hirsutism. Acta Med Okayama. 2003;57(2):73-6.
119. Beigi A, Sobhi A, Zarrinkoub F. Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. Int J Gynaecol Obstet. 2004;87(1):29-33.
120. Van der Spuy ZM, le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev. 2003;(4):CD001125.
121. Venturoli S, Paradisi R, Bagnoli A, Colombo FM, Ravaioli B, Vianello F, Mancini F, et al. Low-dose flutamide (125 mg/day) as maintenance therapy in the treatment of hirsutism. Horm Res. 2001;56:25-31.
122. Taner C, Ýnal M, Bapodul Ö, Önodlu A, Karanfil C, Týnar P, Ýspahi Ç. Comparison of the clinical efficacy and safety of flutamide versus flutamide plus an oral contraceptive in the treatment of hirsutism. Gynecol Obstet. Invest. 2002;54(2):105-8.
123. Ibáñez L, de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum Reprod Update. 2006 May-Jun;12(3):243-52.
124. Tartagni M, Schonauer MM, Cicinelli E, Petruzzelli F, De Pergola G, De Salvia MA, Loverro G. Intermittent low-dose finasteride is as effective as daily administration for the treatment of hirsute women. Fertil Steril. 2004;82(3):752-5.
125. Townsend KA, Marlowe KF. Relative safety and efficacy of finasteride for treatment of hirsutism. Ann Pharmacother. 2004;38(6):1070-3.
126. Fruzzetti F, Bersi C, Parrini D, Ricci C, Genazzani AR. Treatment of hirsutism: comparisons between different antiandrogens with central and peripheral effects. Fertil Steril. 1999;71(3):445-51.
127. Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F, Caputo M, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2000;85(1):89-94.
128. De Leo V, Musacchio MC, Morgante G, Piomboni P, Petraglia F. Metformin treatment is effective in obese teenage girls with PCOS. Hum Reprod. 2006;21(9):2252-6.
129. Krstevska B, Dimitrovski Ch, Pemovska G, Misevska S, Dimova Z, Simeonova S, Ahmeti I. Metformin improves menstrual patterns, endocrine and metabolic profile in obese hyperinsulinemic women with a polycystic ovary syndrome. Prilozi. 2006;27(1):57-66.
130. Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care. 2007;30(3):471-8.
131. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001;86:1626-32.
132. Lemay A, Dodin S, Turcot L, Déchêne F, Forest JC. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Hum Reprod. 2006;21(1):121-8.
133. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 2007;24(1):CD005552.
134. Yýlmaz M, Karakoç A, Törüner FB, Çakýr N, Tiras B, Ayvaz G, Arslan M. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol. 2005;21(3):154-60.
135. Yýlmaz M, Biri A, Karakoç A, Törüner F, Bingöl B, Çakýr N, Tiras B, et al. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. J Endocrinol Invest. 2005;28(11):1003-8.
136. Ibáñez L, López-Bermejo A, del Rio L, Enríquez G, Valls C, de Zegher F. Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess. J Clin Endocrinol Metab. 2007;92(5):1710-4.
137. Balfour JA, McClellan K. Topical eflornithine. Am J Clin Dermatol. 2001;2:197-201.
138. Smith SR, Piacquadio DJ, Beger B, Littler C. Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial. Dermatol Surg. 2006;32(10):1237-43.
139. Richards RN, Meharg GE. Electrolysis: observations from 13 years and 140,000 hours of experience. J Am Acad Dermatol. 1995;33:662-6.
140. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988;124:869-71.
141. Williams R, Havoonjian H, Isagholian K, Menaker G, Moy R. A clinical study of hair removal using the long-pulsed ruby laser. Dermatol. 1998;24:837-42.
142. Greppi I. Diode laser hair removal of the black patient. Lasers Surg Med. 2001;28:150-5.
143. Battle EF, Hobbs LM. Laser-assisted hair removal for darker skin types. Dermatol Ther. 2004;17:177-83.
144. Liew SH, Grobbelaar A, Gault D, Sander R, Green C, Linge C. Hair removal using the ruby laser: clinical efficacy in Fitzpatrick skin type I-V and histological changes in epidermal melanocytes. Br J Dermatol. 1999;140:1105-9.
145. Sanchez LA, Perez M, Azziz R. Laser hair reduction in the hirsute patient: a critical assessment. Hum Reprod Update. 2002;8:169-81.
146. Haedersdal M, Wulf HC. Evidence-based review of hair removal using lasers and light sources. J Eur Acad Dermatol Venereol. 2006;20:9-20.
147. Stanczyk FZ. Diagnosis of hyperandrogenism: biochemical criteria. Best Pract Res Clin Endocrinol Metab. 2006 Jun;20(2):177-91.